Figure 3. Kaplan-Meier plots for overall survival for patients with KRAS wild type (19 statin-users and 145 nonusers) and KRAS mutant tumors (16 statin-users and 83 nonusers) treated with capecitabine, oxaliplatin, bevacizumab and cetuximab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.